If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.The profile contains critical company information including:- Business description – A detailed description of the company’s operations and business divisions.- Corporate strategy – Analyst’s summarization of the company’s business strategy.- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.- Company history – Progression of key events associated with the company.- Major products and services – A list of major products, services and brands of the company.- Key competitors – A list of key competitors to the company.- Key employees – A list of the key executives of the company.- Executive biographies – A brief summary of the executives’ employment history.- Key operational heads – A list of personnel heading key departments/functions.- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.HighlightsNovozymes A/S (Novozymes) is a biotech company. Its core business includes industrial enzymes, microorganisms, biopolymers and biopharmaceutical ingredients. The company develops, produces and distributes enzymes for detergent, technical, food and feed industries. It supplies a range of microorganisms for use in agriculture, industrial cleaning and wastewater treatment. Novozymes provides various biopharmaceutical ingredients for the pharmaceutical industry. The company caters products to various industries such as household care, agriculture, biopharmaceuticals, bioenergy, food and beverages, pulp and paper, leather, wastewater and textiles. It operates in various countries including Denmark, Austria, Japan, India, Sweden, Brazil, Canada, China, the UK and Spain. Novozymes is headquartered in Bagsvaerd, Denmark.Novozymes AS Key Recent DevelopmentsMay 05, 2015: Novozymes to supply enzymes to St1 Biofuels in FinlandApr 23, 2015: Novozymes Interim report for the first 3 months of 2015Jan 29, 2015: India’s Punjab state plans to set up Asia's first bio-ethanol facilityNov 18, 2013: M&G Chemicals JV to construct Chinese glycols biorefineryOct 09, 2013: World’s first advanced biofuels facility opensKey benefits of buying this profile include:You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.Gain key insights into the company for academic or business research.- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
Table of ContentsTable of Contents 2List of Tables 4List of Figures 5Section 1 - About the Company 6Novozymes A/S - Key Facts 6Novozymes A/S - Key Employees 7Novozymes A/S - Key Employee Biographies 8Novozymes A/S - Major Products and Services 9Novozymes A/S - History 10Novozymes A/S - Company Statement 14Novozymes A/S - Locations And Subsidiaries 15Head Office 15Other Locations & Subsidiaries 15Section 2 – Company Analysis 18Novozymes A/S - Business Description 18Novozymes A/S - Corporate Strategy 19Novozymes A/S - SWOT Analysis 20SWOT Analysis - Overview 20Novozymes A/S - Strengths 20Strength - Leading Market Position 20Strength - Diversified End Markets 20Strength - Sound Operational Performance 20Novozymes A/S - Weaknesses 21Weakness - Customer Concentration 21Novozymes A/S - Opportunities 22Opportunity - Growing Demand for Industrial Enzymes 22Opportunity - New Product Launches 22Opportunity - Strategic Initiatives 22Novozymes A/S - Threats 23Threat - Intense Competition 23Threat - Stringent Government Regulations 23Threat - Uncertain R&D Outcomes 23Novozymes A/S - Key Competitors 24Section 3 – Company Financial Ratios 25Financial Ratios - Capital Market Ratios 25Financial Ratios - Annual Ratios 26Performance Chart 28Financial Performance 28Financial Ratios - Interim Ratios 29Financial Ratios - Ratio Charts 30Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances 31Novozymes A/S, Power, Deals By Year, 2009 to YTD 2015 31Novozymes A/S, Power, Deals By Type, 2009 to YTD 2015 32Novozymes A/S, Recent Deals Summary 33Section 5 – Company’s Recent Developments 34May 05, 2015: Novozymes to supply enzymes to St1 Biofuels in Finland 34Apr 23, 2015: Novozymes Interim report for the first 3 months of 2015 35Jan 29, 2015: India’s Punjab state plans to set up Asia's first bio-ethanol facility 36Dec 02, 2014: New enzyme technology converts waste oils into biodiesel 37Dec 02, 2014: Payback for biodiesel producers 38Jul 09, 2014: Europe plants €3.7 billion in the biobased economy 39Jul 08, 2014: Danish bio refinery receives EU funding 40Apr 24, 2014: Novozymes announces interim report for the first 3 months of 2014 41Feb 24, 2014: The Inter-American Development Bank and Novozymes to support the development of sustainable bioenergy solutions 42Feb 10, 2014: Novozymes and Monsanto complete closing of The BioAg Alliance 43Section 6 – Appendix 44Methodology 44Ratio Definitions 44About GlobalData 48Contact Us 48Disclaimer 48List of TablesNovozymes A/S, Key Facts 6Novozymes A/S, Key Employees 7Novozymes A/S, Key Employee Biographies 8Novozymes A/S, Major Products and Services 9Novozymes A/S, History 10Novozymes A/S, Other Locations 15Novozymes A/S, Subsidiaries 15Novozymes A/S, Key Competitors 24Novozymes A/S, Ratios based on current share price 25Novozymes A/S, Annual Ratios 26Novozymes A/S, Interim Ratios 29Novozymes A/S, Power, Deals By Year, 2009 to YTD 2015 31Novozymes A/S, Power, Deals By Type, 2009 to YTD 2015 32Novozymes A/S, Recent Deals Summary 33Currency Codes 44Capital Market Ratios 44Equity Ratios 45Profitability Ratios 45Cost Ratios 46Liquidity Ratios 46Leverage Ratios 47Efficiency Ratios 47List of FiguresNovozymes A/S, Performance Chart (2010 - 2014) 28Novozymes A/S, Ratio Charts 30Novozymes A/S, Power, Deals By Year, 2009 to YTD 2015 31Novozymes A/S, Power, Deals by Type, 2009 to YTD 2015 32